TissueGene Business Development and Alliances:

TissueGene recognizes that in order to prosper in today’s economic climate, strategic alliances are an essential component of a successful business model. TissueGene is prioritizing key components of its discovery process and using its strength in developing business relationships, in order to accomplish the necessary research goals in the most optimal and efficient manner.

We are currently in the process of strategic pharmaceutical alliance recruitment, and are aiming to be an essential partner in the field of cell-therapy and regenerative medicine. We are always seeking relevant partners in areas of strategic interest, including neurology, rheumatology, and orthopedics. We currently select partners based on a variety of criteria but ultimately keeping in mind that it is essential to have a complementary business vision.

  Applications and Markets

The Company’s technology can be used to treat and repair damaged tendons, ligaments, cartilage and bones. Initially, the Company is focusing on providing a permanent cure for osteoarthritis (OA), a debilitating condition that affects approximately one out of every seven people. Currently, the medical costs associated with OA are over $16 Billion per year in the United States alone.

Expanding out into other clinical areas, Tissuegene will focus on similar applications in sports medicine (ligament and tendon repair especially) and degenerative disorders such as diabetic fracture healing and osteoporosis. Finally, TissueGene will utilize the experience gained from the first two focus areas to expand out into other areas.

TissueGene considers the following areas our top business priority:

Licensing of complimentary therapeutics
Gene and/or Immunoregulation through RNAi
Cell mediated therapy delivery mechanisms
Mechanisms of Tissue Regeneration
Complementary yet not competitive technologies and target discovery platforms